Found 42 matching trials
The Analysis of Immuno-Nutrition Index in Advanced Gastric Cancer Receiving Preoperative Treatments
N/ABased on multiple studies, the immune (systemic inflammation) and nutrition...
Location
Peking University Cancer Hospital
Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination With Nivolumab vs. Nivolumab
PHASE2The main goal of this research study is to determine how nivolumab and nivo...
Location
UPMC Hillman Cancer Center
Neoadjuvant Immunochemotherapy for Adenocarcinoma of the Esophagogastric Junction
PHASE2The investigators will conduct a prospective phase 2 study to evaluate the ...
Location
Shanghai Chest Hospital
Impact of Immuno-Oncologic Agent on Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
N/AIt analyzes the Tumor microenvironment(TME) changes in non pathologic compl...
Location
Samsung Medical Center
Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC
PHASE2Standard treatment for stage III Non-Small Cells Lung Cancer (NSCLC) not el...
Location
Gustave Roussy Institute
A Study of Immunotherapy Combined With Neoadjuvant Therapy Versus Neoadjuvant Therapy for Breast Cancer
PHASE2This is a randomized, open label Phase II neoadjuvant study comparing the e...
Location
ShengJing ospital of China Medical University
Perioperative HLX10 (Serplulimab) With S-1+Oxaliplatin (SOX) in Locally Advanced and PD-L1-Positive Gastric or Esophagogastric Junction Adenocarcinoma
PHASE2To evaluate the clinical efficacy of perioperative treatment with S-1 + oxa...
Location
Chiba Cancer Center
Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL
PHASE2In the treatment of Ph-negative (Ph-) B-cell acute lymphoblastic leukemia (...
Location
Institute of Hematology & Blood Diseases Hospital
Adebrelimab Combined With Albumin Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Resectable ESCC
PHASE2This is a multi-center, single-arm, phase II clinical study designed to obs...
Location
Multiple Locations
Integrating Multimodal AI to Predict Treatment Response and Refine Risk Stratification in Esophageal Cancer (Radiogenomics-Esophagus)
N/AThis AI-driven model leverages multimodal data-such as radiomics, pathomics...
Location
Tongji hospital, Tongji medical college, Huazhong university of science and technology